MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia. Nature Communications. 2020; 11:2369.
.High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy. Blood Advances. 2020; 4:717-727.
.Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI insight. 2017; 2:e89473.
.LAMP-5 is an essential inflammatory-signaling regulator and novel immunotherapy target for mixed lineage leukemia-rearranged acute leukemia. Haematologica: the hematology journal. 2022; 107:803-815.
.TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Cell Stem Cell. 2022; 29:298-314.e9.
.An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML. Cancer Discovery. 2022; 12:432-449.
.Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective. Pediatric Blood and Cancer. 2021; 68:e29126.
.2020; 38:e22502.
. Methylation profiling of hypomethylating agent response and treatment failure in pediatric and young adult MDS/AML. Journal of Clinical Oncology.MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia. Nature Communications. 2020; 11:2369.
.High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy. Blood Advances. 2020; 4:717-727.
.